Bleeding by on-treatment parameters
bleeding
EVENTS, BLEEDING, BLEEDS
There was a significant difference across the severity of bleeding events in regard to adherence to all of the first week of randomised treatment and for the STime course of bleeding by antiplatelet regimen for epochs 0–7, 8–35 and 36–90 days. (Fatal or major bleeds were relatively infrequent occurring in 39 (2.5%) participants randomised to triple antiplatelet therapy, 12 (1.4%) randomised to clopidogrel, and 5 (0.7%) randomised to aspirin and dipyridamole. Major or fatal bleeding was increased with intensive vs. guideline antiplatelets: 39 vs. 17 participants, adjusted hazard ratio 2.21, 95% CI 1.24–3.93, 